Ensayos clínicos
Evolocumab
Comercialización: Repatha: Europa (EMA), EE.UU. (FDA)
Study to Assess In-home Use of Evolocumab (AMG 145) Using a Prefilled Syringe or a Prefilled Autoinjector/Pen
Estado: Completado - Resultados Publicados
Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk
Estado: Completado - Resultados Publicados
Ascending Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Evolocumab (AMG 145) in Adults With Hyperlipidemia on Stable Doses of a Statin
Estado: Completado - Resultados Publicados
A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects
Estado: Completado - Resultados Publicados
Trial Assessing Evolocumab (AMG 145) Compared to LDL-C Apheresis in Subjects Receiving LDL-C Apheresis Prior to Study Enrollment
Estado: Completado
Estimation Study to Assess the Effect of Severe Renal Impairment and ESRD Hemodialysis on the PK of Evolocumab (AMG 145)
Estado: Completado - Resultados Publicados
Extension (OLE) Study to Assess Safety and Efficacy of Evolocumab
Estado: Completado - Activo, no reclutando
Monoclonal Antibody Against PCSK9 to Reduce Elevated Low-density Lipoprotein Cholesterol (LDL-C) in Adults Currently Not Receiving Drug Therapy for Easing Lipid Levels
Estado: Completado - Resultados Publicados
LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy
Estado: Completado - Resultados Publicados
Trial Evaluating PCSK9 Antibody in Subjects With LDL Receptor Abnormalities
Estado: Completado - Resultados Publicados
Durable Effect of PCSK9 Antibody Compared with Placebo Study
Estado: Completado - Resultados Publicados
Reduction of Low-Density Lipoprotein Cholesterol (LDL-C) With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study
Estado: Completado - Resultados Publicados
Study to Assess in Home Use of Evolocumab (AMG 145) Administration Using Either an Automated Mini-doser or a Prefilled Autoinjector/Pen
Estado: Completado - Resultados Publicados
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-3
Estado: Activo, no reclutando - Resultados Publicados
Trial Assessing Long Term USe of PCSK9 Inhibition in Subjects With Genetic LDL Disorders
Estado: Activo, no reclutando - Resultados Publicados
Trial Assessing Efficacy, Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders
Estado: Reclutando
Global Assessment of Plaque Regression With a PCSK9 Antibody as Measured by Intravascular Ultrasound
Estado: Completado - Resultados Publicados
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
Estado: Completado - Resultados Publicados
Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder Study-2
Estado: Completado - Resultados Publicados
Open Label Study of Long Term Evaluation Against LDL-C Trial-2
Estado: Activo, no reclutando - Resultados Publicados
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects -2
Estado: Completado - Resultados Publicados
Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Subjects Currently Not Receiving Drug Therapy for Easing Lipid Levels-2
Estado: Completado - Resultados Publicados
Open Label Study of Long Term Evaluation Against LDL-C Trial
Estado: Activo, no reclutando - Resultados Publicados
Evaluating PCSK9 Binding Antibody Influence on Cognitive Health in High Cardiovascular Risk Subjects
Estado: Completado
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk
Estado: Completado - Resultados Publicados
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
Estado: Reclutando
LDL-C Assessment w/ PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Estado: Completado - Resultados Publicados
Effects of PCSK9 Inhibition by Evolocumab on Postprandial Lipid Metabolism in Type 2 Diabetes
Estado: Reclutando
Evolocumab Pregnancy Exposure Registry
Estado: Reclutando
Impact of Evolocumab on the Effects of Clopidogrel in Patients With High On-Treatment Platelet Reactivity
Estado: Reclutando
Open Label Study to Evaluate Safety, Tolerability and Efficacy of Evolocumab (AMG 145) in Pediatric Subjects (10 to 17 Years of Age) With Heterozygous Familial
Estado: Reclutando
An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol
Estado: Sin reclutar
Safety, Tolerability & Efficacy on LDL-C of Evolocumab in Subjects With HIV & Hyperlipidemia/Mixed Dyslipidemia
Estado: Sin reclutar
Fourier Open-label Extension Study in Subjects With Clinically Evident Cardiovascular Disease in Selected European Countries
Estado: Reclutando
A Study in Subjects With Type 2 Diabetes Mellitus With Hypercholesterolemia/Mixed Dyslipidemia
Estado: Reclutando
Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk Open-label Extension
Estado: Activo, no reclutando
Long Term Post Marketing Specified Drug Use Result Survey for Evolocumab in Japan
Estado: Reclutando
Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects-4
Estado: Reclutando
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibition on Arterial Wall Inflamation Study in Patients With Elevated Lipoprotein(a) (Lp(a)).
Estado: Reclutando
Chart Review of Repatha® in Subjects With Hyperlipidaemia
Estado: Reclutando
A Double-blind, Randomized Study in Diabetic Subjects With Hyperlipidemia or Mixed Dyslipidemia
Estado: Reclutando
Study to Evaluate the Safety of Repatha® in Pregnancy
Estado: Reclutando
Vascular Inflammation and Cholesterol Lowering Therapy
Estado: Sin reclutar
Prospective German Very High Cardiovascular Risk Patients Dyslipidemia Treatment Indication Registry
Estado: Sin reclutar
